BioCentury
ARTICLE | Company News

Amarantus BioScience, University of Massachusetts deal

March 10, 2014 7:00 AM UTC

Amarantus and the university entered an exclusive option agreement to license the university's method of use IP on the use of mesencephalic astrocyte-derived neurotrophic factor (MANF; ARP; ARMET)-family proteins for antibiotic-induced ototoxicity and other ear disorders. Amarantus said it paid $1,000 for the option, which has an 18-month term. ...